Theravance Biopharma TBPH Future Royalty Payment Contingencies
Future Royalty Payment Contingencies at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept tbph:FutureRoyaltyPaymentContingencies.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's future royalty payment contingencies.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's future royalty payment contingencies?
- Theravance Biopharma (TBPH) reported future royalty payment contingencies of $32.8M in Q1 2026.
- How has Theravance Biopharma's future royalty payment contingencies changed year-over-year?
- Theravance Biopharma's future royalty payment contingencies increased by 5.9% year-over-year, from $30.98M to $32.8M.
- What is the long-term trend for Theravance Biopharma's future royalty payment contingencies?
- Over 3 years (2022 to 2025), Theravance Biopharma's future royalty payment contingencies has grown at a 8.8% compound annual growth rate (CAGR), from $25.44M to $32.8M.
- What does future royalty payment contingencies mean?
- This metric identifies potential future obligations to pay royalties to third parties based on the commercial success of the company's products. It highlights the long-term cost structure associated with in-licensed technology or intellectual property rights. Understanding these contingencies is essential for evaluating the net profitability of future product sales.